PUMCH Gastroenterology: Pancreatobiliary, IBD and Endoscopy Teams

Where the department sits and what the 2023 listing means

Peking Union Medical College Hospital (PUMCH) is in Beijing and its gastroenterology department traces its development to Zhang Xiaoqian and Chen Minzhang, according to the hospital's own department overview. In the 2023 Fudan national specialty reputation list, the hospital's gastroenterology specialty was placed second nationally. That is a single historical, dated statement about the specialty as a whole. It is not a 2026 ranking, not a statement about any subspecialty, and not a ranking of individual doctors. Treat it as background on how the department has been regarded, not as evidence that a particular problem will be accepted or solved there.

Four documented directions that are not interchangeable

The department overview groups inflammatory bowel disease, pancreatic disease, endoscopy, gastrointestinal functional and motility disease, gastrointestinal neuroendocrine tumours and early gastrointestinal neoplasia as its clinical directions. They sit side by side on one page, but they describe different problems, different records and different kinds of clinical work.

Pancreatic and biliary disease is the clearest illustration. The department's endoscopic work in this area, including ERCP and EUS, is documented in the director's clinical biography, and a patient whose question concerns the bile ducts or pancreas is asking about that strand. Inflammatory bowel disease is a separate direction, documented through clinicians whose interests centre on IBD and complex rare intestinal disorders, and through work on ulcerative colitis. A patient with longstanding colitis should ask how the team would review disease extent, prior medicines and surveillance history, rather than assume a pancreaticobiliary endoscopy review is the relevant route.

Early gastrointestinal neoplasia is listed as a direction in its own right, and the department's documented interests here span both upper-gut lesions such as early gastric cancer and colorectal polyps, screening and prevention research. A patient referred after a polyp or an early lesion has been found should state exactly where the lesion is and what has already been removed or biopsied, because the two areas lead to different questions. Functional and motility disease is a further direction, distinct from therapeutic endoscopy, and gastrointestinal neuroendocrine tumours appear both in the overview and in a documented focus on gastrointestinal and pancreatic neuroendocrine tumours. For that group, the pathology and imaging history shape the question, so it is worth asking which records the team would want to see first.

The people named in the department's own materials

Yang Aiming is the department director and also director of the endoscopy training centre, a chief physician and doctoral supervisor. Wu Dong is identified in the department roster as a hospital vice president and appears among the biliary biopsy forceps research team.

Li Jingnan is a deputy director, chief physician and doctoral supervisor, with documented interests in colon polyps, colorectal-cancer screening and prevention research, chronic pancreatitis, gastrointestinal and pancreatic neuroendocrine tumours, and ulcerative colitis. The biography records contributions to Asia-Pacific colorectal screening guidance and to national colorectal and neuroendocrine consensus guidelines, plus research on colorectal carcinogenesis and on carcinogenesis related to ulcerative colitis. Those are academic contributions, not an individual screening interval or a preventive recommendation for any one patient.

Li Ji is a deputy director, chief physician and master's supervisor whose biography centres on IBD and complex rare intestinal disorders, naming Cronkhite-Canada syndrome, hereditary gastrointestinal hamartomatous polyposis, eosinophilic gastrointestinal disease, and celiac and autoimmune intestinal disease. It also records editing the PUMCH internal-medicine resident handbook and hosting a journal MDT discussion column. A patient with one of these rare diagnoses should ask whether the described interest matches the records, rather than assume the department will accept every referral.

These are different people with different documented emphases, so a referral question should name the problem and the records that support it, rather than ask for the most senior name.

Research at PUMCH gastroenterology and what it does not promise

A hospital report dated 29 September 2026 describes work by Yang Aiming, Wu Dong, Wu Xi and Wang Qiang on a reverse-opening biliary biopsy forceps. It was single-centre prospective feasibility work, the article was accepted by World Journal of Gastroenterology, and the technology has a patent transfer; multicentre study and product engineering are described as planned. This is device development and early feasibility research, not evidence of regulatory approval, and it does not establish that the instrument is part of routine care for a patient arriving with a biliary problem. A patient should ask the treating team what instrument and approach would actually be used in their own case.

A second report, dated 31 August 2026, covers a Nature Communications study with Li Jingnan as co-corresponding author alongside Yang Qiwen and Wu Bin. It examined a periodontal bacterium, decanoic acid, neutrophils and colorectal tumour biology, combining clinical cohort observations with laboratory and mouse work. This is mechanism research that may point toward future research targets; it is not an approved test or a treatment, and it does not establish what would be offered at a consultation.

Honours: what is attributed, and to whom

Yang Aiming's biography records a national health-authority recognition for outstanding young and middle-aged contributors; no year or grade is given. It is a personal recognition.

The biliary biopsy forceps project carries two attributed recognitions: designation as a Beijing innovative medical device, and a second prize in the endoscopy category of the ninth China medical-device innovation and entrepreneurship competition. Both belong to the project and its team rather than to the department as a whole or to any individual as a personal award.

Questions worth settling before an overseas visit

The first question is which direction your records actually fall under, and whether the department's documented work in that area matches your problem. The second is what the treating team would want to review first, and which existing reports, images or pathology material it considers relevant; the receiving clinician decides that, not the patient's own list.

Ask, too, how a complex case would be reviewed across specialties, since pancreaticobiliary disease and rare intestinal disorders can involve more than one service. Confirm what the hospital's own written plan would include and what would be arranged locally. Suitability and scheduling are decisions for the treating team, and an enquiry does not reserve anything.

Digestive disease care at ChinaSpecialistCare

How ChinaSpecialistCare can help with this enquiry

ChinaSpecialistCare can help an overseas patient prepare a short summary of the diagnosis and main question, request a specialist appointment or a records-based opinion for a gastroenterology case, and arrange interpretation. Coordination fees are separate from hospital charges; the treating clinicians decide what records and tests are needed, and the hospital decides acceptance and suitability.